Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?

H Puzantian, R Townsend… - The Journal of Clinical …, 2024 - Wiley Online Library
The obesity pandemic, with its associated comorbidities of hypertension and diabetes,
constitutes a global public health issue. Importantly, there is an increasing prevalence of …

Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease

I Lima Posada, M Soulié, Y Stephan… - Journal of the …, 2024 - ahajournals.org
Background The mineralocorticoid receptor plays a significant role in the development of
chronic kidney disease (CKD) and associated cardiovascular complications. Classic …

New perspectives on sex Steroid and Mineralocorticoid receptor signaling in cardiac ischemic injury

LA Bienvenu, JR Bell, KL Weeks… - Frontiers in …, 2022 - frontiersin.org
The global burden of ischemic heart disease is burgeoning for both men and women.
Although advances have been made, the need for new sex-specific therapies targeting key …

Effectiveness of spironolactone in terms of galectin-3 levels in patients with heart failure with a reduced ejection fraction in the vietnamese population

SK Tran, TH Ngo, TT Lai, GK Truong, KDD Tran, PM Vo… - Healthcare, 2023 - mdpi.com
Background: Galectin-3 is a biomarker that has been demonstrated to play a significant role
in myocardial fibrosis and remodeling in the pathogenesis of heart failure. Furthermore …

Rising Prevalence of Obesity and Primary Hyperaldosteronism: Co-incidence or Connected Circumstances Leading to Hypertension? A Narrative Review

S Bansal, H Puzantian, RR Townsend - Journal of general internal …, 2024 - Springer
While obesity and its associated complications, mainly diabetes and hypertension, have
been the largest public health problems of modern world, the emerging data suggests an …

Albuminuria and cardiorenal risk

PI Georgianos, E Dounousi… - Current Opinion in …, 2023 - journals.lww.com
The broader implementation of albuminuria assessment in daily clinical practice facilitates
the identification of high-risk patients with early-stage CKD who are candidates for treatment …

Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment: results from the Aldo-DHF trial

M Schnelle, A Leha, A Eidizadeh, K Fuhlrott, TD Trippel… - Cells, 2021 - mdpi.com
The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly
understood and therapeutic strategies are lacking. This study aimed to identify plasma …

[HTML][HTML] Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment

X Huang, L Hu, Z Long, X Wang, J Wu… - Reviews in …, 2024 - imrpress.com
Hypertensive heart disease (HHD) presents a substantial global health burden, spanning a
spectrum from subtle cardiac functional alterations to overt heart failure. In this …

The role of the non-steroidal mineralocorticoid antagonist finerenone in cardiorenal management

CJ Beavers - Current Cardiology Reports, 2022 - Springer
Abstract Purpose of Review Finerenone is a novel, non-steroidal mineralocorticoid receptor
antagonist (MRAs) that has been investigated for the management of cardiorenal conditions …

Association of Left and Right Branch Blocks with Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction

S Reddy, L Kattamuri, A Dwivedi… - … Journal of Angiology, 2025 - thieme-connect.com
The associations of left bundle branch block (LBBB) and right bundle branch block (RBBB)
with cardiovascular (CV) outcomes compared with normal QRS in heart failure patients with …